SMT202100367T1 - Derivati di indoli mono- o di-sostituti come inibitori della replicazione del virus dengue - Google Patents

Derivati di indoli mono- o di-sostituti come inibitori della replicazione del virus dengue

Info

Publication number
SMT202100367T1
SMT202100367T1 SM20210367T SMT202100367T SMT202100367T1 SM T202100367 T1 SMT202100367 T1 SM T202100367T1 SM 20210367 T SM20210367 T SM 20210367T SM T202100367 T SMT202100367 T SM T202100367T SM T202100367 T1 SMT202100367 T1 SM T202100367T1
Authority
SM
San Marino
Prior art keywords
mono
viral replication
indole derivatives
substituted indole
replication inhibitors
Prior art date
Application number
SM20210367T
Other languages
English (en)
Italian (it)
Inventor
Pierre Jean-Marie Bernard Raboisson
Tim Hugo Maria Jonckers
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SMT202100367T1 publication Critical patent/SMT202100367T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20210367T 2015-05-08 2016-05-04 Derivati di indoli mono- o di-sostituti come inibitori della replicazione del virus dengue SMT202100367T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31
EP16723965.6A EP3294738B1 (en) 2015-05-08 2016-05-04 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PCT/EP2016/059975 WO2016180696A1 (en) 2015-05-08 2016-05-04 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
SMT202100367T1 true SMT202100367T1 (it) 2021-07-12

Family

ID=56026812

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210367T SMT202100367T1 (it) 2015-05-08 2016-05-04 Derivati di indoli mono- o di-sostituti come inibitori della replicazione del virus dengue

Country Status (39)

Country Link
US (5) US10696632B2 (enExample)
EP (2) EP3294738B1 (enExample)
JP (4) JP6752821B2 (enExample)
KR (2) KR102610493B1 (enExample)
CN (3) CN107873022B (enExample)
AU (2) AU2016259677B2 (enExample)
BR (1) BR112017023904A2 (enExample)
CA (1) CA2981845C (enExample)
CL (1) CL2017002817A1 (enExample)
CO (1) CO2017012381A2 (enExample)
CR (2) CR20200152A (enExample)
CY (1) CY1124548T1 (enExample)
DK (1) DK3294738T3 (enExample)
EA (1) EA034978B1 (enExample)
EC (2) ECSP17073878A (enExample)
ES (2) ES2941674T3 (enExample)
GT (1) GT201700234A (enExample)
HR (1) HRP20210675T1 (enExample)
HU (1) HUE054724T2 (enExample)
IL (2) IL255430B (enExample)
JO (2) JOP20160086B1 (enExample)
LT (1) LT3294738T (enExample)
MD (1) MD3294738T2 (enExample)
MX (2) MX383932B (enExample)
MY (1) MY198339A (enExample)
NI (1) NI201700137A (enExample)
PE (2) PE20221579A1 (enExample)
PH (1) PH12017502000A1 (enExample)
PL (1) PL3294738T3 (enExample)
RS (1) RS62029B1 (enExample)
SG (1) SG10201900315SA (enExample)
SI (1) SI3294738T1 (enExample)
SM (1) SMT202100367T1 (enExample)
SV (1) SV2017005557A (enExample)
TW (2) TWI744963B (enExample)
UA (2) UA121332C2 (enExample)
UY (2) UY36674A (enExample)
WO (1) WO2016180696A1 (enExample)
ZA (2) ZA201707524B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
CA2958022A1 (en) * 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc Mono- or di-substituted indoles as dengue viral replication inhibitors
LT3201176T (lt) * 2014-10-01 2019-03-25 Janssen Pharmaceuticals, Inc. Mono- arba dipakeistieji indolo dariniai kaip dengės viruso replikacijos slopikliai
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10913716B2 (en) 2016-03-31 2021-02-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
EA039702B1 (ru) * 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112022009199A2 (pt) 2019-11-15 2022-07-26 Janssen Pharmaceuticals Inc Tratamento e prevenção da dengue
WO2022094817A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团(天津)股份有限公司 连续化合成取代吲哚-2-羧酸的方法
AU2022304189A1 (en) 2021-06-29 2024-02-15 Janssen Pharmaceuticals, Inc. Processes for the preparation of (s)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1 -(1h-indol-3-yl)ethenone derivatives
EP4522163A1 (en) 2022-05-12 2025-03-19 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
CN119306651B (zh) * 2024-10-11 2025-12-05 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2308443A1 (en) 1997-10-27 1999-05-06 Michael Lyle Denney Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
RU2007130896A (ru) 2005-01-14 2009-02-20 Дженелэбс Текнолоджиз, Инк. (Us) Индольные производные для лечения вирусных инфекций
EA200701669A1 (ru) 2005-02-09 2008-02-28 Мидженикс Инк. Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
CN102186833A (zh) * 2008-08-18 2011-09-14 耶鲁大学 Mif调节剂
WO2010021878A1 (en) * 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
UA108221C2 (uk) 2010-01-15 2015-04-10 Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ES2784841T3 (es) 2014-01-31 2020-10-01 Bristol Myers Squibb Co Macrociclos con grupos aromáticos P2' como inhibidores del factor XIa
EP3152301B1 (en) 2014-06-04 2021-05-05 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists
EA039148B1 (ru) 2014-06-04 2021-12-10 Эмджен Инк. Способ сбора рекомбинантного белка
NO2721243T3 (enExample) 2014-10-01 2018-10-20
LT3201176T (lt) 2014-10-01 2019-03-25 Janssen Pharmaceuticals, Inc. Mono- arba dipakeistieji indolo dariniai kaip dengės viruso replikacijos slopikliai
CA2958022A1 (en) * 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc Mono- or di-substituted indoles as dengue viral replication inhibitors
PT3957753T (pt) 2014-10-10 2024-11-21 The State Univ Of New Jersey Rutgers Primers e sondas da reação em cadeia da polimerase para mycobacterium tuberculosis
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3313816B1 (en) 2015-07-22 2023-05-24 OMEICOS Therapeutics GmbH Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
ES2907686T3 (es) 2015-11-03 2022-04-26 Zoetis Services Llc Compuestos poliméricos sol-gel y sus usos
US10913716B2 (en) 2016-03-31 2021-02-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
JP6788683B2 (ja) 2016-03-31 2020-11-25 武田薬品工業株式会社 複素環化合物
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
WO2017173410A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
UA128781C2 (uk) 2016-04-01 2024-10-23 Кайт Фарма, Інк. Т-клітина, спосіб її отримання та застосування
SG11201808411RA (en) 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018068851B1 (pt) 2016-04-01 2022-11-22 Basf Se Composto de fórmula i, composição, métodos de combate ou controle de pragas invertebradas e de proteção de plantas, semente revestida e uso de pelo menos um composto
JP6573745B2 (ja) 2017-03-17 2019-09-11 三菱電機株式会社 アダプティブアレーアンテナ装置
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체

Also Published As

Publication number Publication date
EP3294738A1 (en) 2018-03-21
TW201704208A (zh) 2017-02-01
CN111303000A (zh) 2020-06-19
UY39706A (es) 2022-05-31
KR20180002644A (ko) 2018-01-08
ZA202002435B (en) 2023-03-29
AU2016259677A1 (en) 2017-10-26
GT201700234A (es) 2018-11-26
UY36674A (es) 2016-11-30
IL272814B (en) 2021-02-28
JP2018515495A (ja) 2018-06-14
ES2877404T3 (es) 2021-11-16
PH12017502000B1 (en) 2018-03-26
CA2981845C (en) 2022-03-08
NI201700137A (es) 2019-05-07
CN107873022A (zh) 2018-04-03
JOP20160086B1 (ar) 2021-08-17
EA034978B1 (ru) 2020-04-14
IL272814A (en) 2020-04-30
PE20180232A1 (es) 2018-01-31
MX383932B (es) 2025-03-14
TWI744963B (zh) 2021-11-01
RS62029B1 (sr) 2021-07-30
KR102610491B1 (ko) 2023-12-06
HK1252496A1 (zh) 2019-05-31
TW202041499A (zh) 2020-11-16
JP7451626B2 (ja) 2024-03-18
CN113045476A (zh) 2021-06-29
JP2022166289A (ja) 2022-11-01
TWI725969B (zh) 2021-05-01
CO2017012381A2 (es) 2018-03-28
CA2981845A1 (en) 2016-11-17
AU2020273314A1 (en) 2020-12-17
CR20170490A (es) 2018-03-08
SI3294738T1 (sl) 2021-08-31
US20210171462A1 (en) 2021-06-10
US10919854B2 (en) 2021-02-16
JP2021138752A (ja) 2021-09-16
HRP20210675T1 (hr) 2021-06-25
DK3294738T3 (da) 2021-06-28
EA201792429A1 (ru) 2018-02-28
US10696632B2 (en) 2020-06-30
ECSP22023220A (es) 2022-05-31
AU2016259677B2 (en) 2020-10-01
IL255430A0 (en) 2017-12-31
LT3294738T (lt) 2021-08-25
JP7132399B2 (ja) 2022-09-06
US11827602B2 (en) 2023-11-28
UA121332C2 (uk) 2020-05-12
CY1124548T1 (el) 2022-07-22
JOP20210109A1 (ar) 2023-01-30
US20240182414A1 (en) 2024-06-06
WO2016180696A1 (en) 2016-11-17
EP3896072A1 (en) 2021-10-20
US20250230127A1 (en) 2025-07-17
JP6898493B2 (ja) 2021-07-07
JP6752821B2 (ja) 2020-09-09
IL255430B (en) 2020-03-31
CN107873022B (zh) 2021-03-12
ZA201707524B (en) 2024-06-26
CN111303000B (zh) 2023-11-28
ECSP17073878A (es) 2018-02-28
US12172959B2 (en) 2024-12-24
PE20221579A1 (es) 2022-10-06
NZ765879A (en) 2024-09-27
AU2020273314B2 (en) 2021-10-21
MX2020011156A (es) 2022-04-21
SG10201900315SA (en) 2019-02-27
US20180346419A1 (en) 2018-12-06
BR112017023904A2 (pt) 2018-07-17
CN113045476B (zh) 2024-07-16
UA128183C2 (uk) 2024-05-01
US20200270209A1 (en) 2020-08-27
MD3294738T2 (ro) 2021-08-31
MY198339A (en) 2023-08-27
CR20200152A (es) 2020-09-08
MX2017014293A (es) 2018-08-09
EP3294738B1 (en) 2021-04-07
CL2017002817A1 (es) 2018-05-11
JP2020125316A (ja) 2020-08-20
SV2017005557A (es) 2018-06-26
PH12017502000A1 (en) 2018-03-26
KR102610493B1 (ko) 2023-12-05
KR20210048578A (ko) 2021-05-03
NZ736934A (en) 2023-11-24
HUE054724T2 (hu) 2021-09-28
PL3294738T3 (pl) 2021-12-13
ES2941674T3 (es) 2023-05-24
HK1252446A1 (zh) 2019-05-24
EP3896072B1 (en) 2022-11-16
MX391754B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
ZA202002435B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
IL258043B (en) Mono- or di-converted indoles as inhibitors of dengue virus replication
ZA201801764B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
ZA201702301B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
ZA201702299B (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
ZA201806482B (en) Substituted indoline derivatives as dengue viral replication inhibitors
ZA201806473B (en) Substituted indole derivatives as dengue viral replication inhibitors
IL261943A (en) Transformed indulin derivatives as inhibitors of dengue virus replication
ZA201704783B (en) Indole derivatives as dengue viral replication inhibitors
IL261947A (en) History of converted indole compounds as inhibitors of dengue virus replication
PT3294738T (pt) Derivados mono ou di-substituídos de indol como inibidores da replicação viral da dengue